NasdaqCM - Nasdaq Real Time Price USD

Anebulo Pharmaceuticals, Inc. (ANEB)

2.2850 -0.1250 (-5.19%)
As of 2:56 PM EDT. Market Open.
Loading Chart for ANEB
DELL
  • Previous Close 2.4100
  • Open 2.5100
  • Bid --
  • Ask --
  • Day's Range 2.2101 - 2.5100
  • 52 Week Range 1.6200 - 4.0500
  • Volume 13,660
  • Avg. Volume 5,911
  • Market Cap (intraday) 59.257M
  • Beta (5Y Monthly) -0.99
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4100
  • Earnings Date May 9, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.00

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

www.anebulo.com

2

Full Time Employees

June 30

Fiscal Year Ends

Recent News: ANEB

Performance Overview: ANEB

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ANEB
5.58%
S&P 500
9.96%

1-Year Return

ANEB
1.72%
S&P 500
27.18%

3-Year Return

ANEB
67.36%
S&P 500
27.54%

5-Year Return

ANEB
--
S&P 500
23.92%

Compare To: ANEB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ANEB

Valuation Measures

Annual
As of 5/13/2024
  • Market Cap

    62.50M

  • Enterprise Value

    55.85M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    9.63

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -54.65%

  • Return on Equity (ttm)

    -95.37%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.49M

  • Diluted EPS (ttm)

    -0.4100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.64M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -5.77M

Research Analysis: ANEB

Company Insights: ANEB

Research Reports: ANEB

People Also Watch